Study S000701

A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Exenatide Implant

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05670379
Acronym: LIBERATE-1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 24
Start: 2024-12-20
Primary completion: 2025-08-21
Lead sponsor: Vivani Medical, Inc
Conditions: Overweight and Obesity; Type2diabetes
Interventions: COMBINATION_PRODUCT:Exenatide Implant; DRUG:Bydureon BCise (exenatide extended release); DRUG:Semaglutide, 1.0 mg/mL
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Area under the plasma concentration-time curve (AUC) [9 weeks]
Maximum plasma concentration observed (Cmax) [9 weeks]
Time to maximum plasma concentration observed (Tmax) [9 weeks]
Adverse events [9 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.